Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 10/20 | 0.36 |
| ▸ | CCND1 | P24385 | 10/20 | 0.36 |
| ▸ | CCND3 | P30281 | 10/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 10/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9897630 | 1.00 | CDK4 (0.36) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9898005 | 0.97 | CDK4 (0.36) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9898001 | 0.97 | CDK4 (0.36) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9896138 | 0.97 | CDK4 (0.36) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9896136 | 0.97 | CDK4 (0.36) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9899931 | 0.95 | CDK4 (0.33) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL9896714 | 0.95 | CDK4 (0.33) | CDK4CCND1CCND3CDK6TBK1 | |
| SCHEMBL1438638 | 0.95 | RIPK1 (0.32) | CDK4CCND1CCND3CDK6FFAR4 | |
| SCHEMBL1438639 | 0.95 | RIPK1 (0.32) | CDK4CCND1CCND3CDK6FFAR4 | |
| SCHEMBL9898123 | 0.93 | CDK4 (0.37) | CDK4CCND1CCND3CDK6TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | claimed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | claimed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | CDK4 289/4885CCND1 1137/4885CCND3 784/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | CDK4 349/4885CCND1 1156/4885CCND3 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.